News | August 15, 2014

First Human Implants of VenTouch Ventricular Reshaping Device Performed in Malaysia

Global clinical trial in patients with functional mitral valve regurgitation underway

August 15, 2014 — Mardil Medical announced earlier this year the first-in-human implants using the VenTouch ventricular reshaping device performed by a surgical team at the Institut Jantung Negara (IJN) National Heart Institute in Kuala Lumpur, Malaysia. This novel, investigational device was implanted in two patients with severe functional mitral valve regurgitation (FMR), which was reduced to only trace amounts after implantation. The patients are part of a multicenter, global clinical study.

Jeswant Dillon, M.D., clinical director of adult surgery, and Mohd Azhari Yakub, M.D., chief cardiothoracic surgeon, performed the implantations at IJN. The first patient presented several challenges due to severe FMR combined with significant heart dilation and poor left ventricular function.

“After implantation of the VenTouch system’s therapy device, the patient’s mitral valve regurgitation was reduced to trace amounts and the patient was moved out of the intensive care unit the following day,” said Dillon. “Our heart team was fascinated with the ease of placement, the immediate performance of the therapy device and the rapid recovery of the very sick patients.”

The procedures were also attended and supported by William Cohn, M.D., FACS, FACCP, FAHA, director of minimally invasive cardiac surgery at the Texas Heart Institute in Houston; Eugene Grossi, M.D., director of cardiac research at New York University Medical Center; and Vivek Rao, M.D., Ph.D., MSc, FRCSC, chief of cardiac surgery at Toronto General Hospital.

“The VenTouch system is a promising technology that addresses both the annular and muscular abnormalities associated with FMR,” said Cohn. “I was extremely impressed with the marked reduction in regurgitation we were able to demonstrate after a quick, off-pump procedure through a small incision.”

FMR occurs when the left ventricle of the heart is enlarged and the mitral valve no longer closes properly. With each heartbeat, blood leaks backwards into lungs, creating debilitating symptoms. If left untreated, FMR overloads the heart and can lead to or accelerate heart failure. The current treatment for FMR is repairing the mitral valve, an open-heart surgical procedure on a bypass pump, which can be difficult to perform and risky for sicker patients. Even after successful repair surgery, FMR can reoccur because the ventricle often continues to get larger.

"Having now successfully treated patients with the VenTouch system, Mardil has taken an important step towards our goal of introducing this ground breaking therapy and giving FMR patients a promising and significantly less invasive treatment option,” said Jim Buck, president and CEO of Mardil Medical.

The VenTouch system is the only device that treats the root cause of FMR – the enlarged, injured left ventricle. The system’s delivery tool deploys the therapy device through a small incision between the ribs and guides it over the beating heart. The therapy device is a biomaterial sleeve fitted with an inflatable, adjustable fluid chamber which applies prescriptive pressure to a targeted location in order to realign valve leaflets, stopping the leaking by improving the shape and reducing the stress of the enlarged heart. If any further changes in the left ventricle occur after implantation, the VenTouch can be adjusted using a remote port.

For more information: www.mardil.com

Related Content

Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

Feature | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femor
The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.  #SCAI, #SCAI2018

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.

News | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict par
First-Ever Risk Tool Helps Predict TAVR Readmission Rates in 2018 SCAI late-breaking study. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing...
Medtronic Shares Two-Year Harmony Transcatheter Pulmonary Valve Results at SCAI 2018. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
Medtronic plc announced two-year outcomes for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
Colibri Heart Valve Continues Enrollment in TAVI Early Feasibility Study
News | Heart Valve Technology | May 07, 2018
Colibri Heart Valve LLC announced the Colibri transcatheter aortic valve implantation (TAVI) System has been used on an...
An 3D echo view of a Neovasc Tiara transcatheter mitral valve. This valve is currently in clinical trials and is ahead of most of the TMVR devices in development.

A 3-D echo view of a Neovasc Tiara transcatheter mitral valve. This valve is currently in clinical trials and is ahead of most of the TMVR devices in development.

Feature | Heart Valve Technology | May 04, 2018 | Dave Fornell, Editor
May 4, 2018 — Transcatheter val...
Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy - Cardioband Tricuspid Valve Reconstruction System
News | Heart Valve Technology | May 01, 2018
Edwards Lifesciences Corp.announced that it received CE Mark for the Edwards Cardioband Tricuspid Valve Reconstruction...
Overlay Init